These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10573104)

  • 21. A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Kikuchi K
    Am J Clin Oncol; 1994 Apr; 17(2):103-8. PubMed ID: 8141101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental combined chemo- and endocrine therapy with UFT and tamoxifen in human breast carcinoma xenografts serially transplanted into nude mice].
    Kubota T; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
    Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2767-73. PubMed ID: 2074386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
    Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
    Ohashi Y; Watanabe T; Sano M; Koyama H; Inaji H; Suzuki T
    Breast Cancer Res Treat; 2010 Feb; 119(3):633-41. PubMed ID: 19936917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
    Takuwa H; Saji S; Takada M; Takahara S; Yamauchi A
    Breast Dis; 2018; 37(4):185-190. PubMed ID: 29578459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.
    Sugimachi K; Maehara Y; Ogawa M; Kakegawa T; Tomita M
    Cancer Chemother Pharmacol; 1997; 40(3):233-8. PubMed ID: 9219507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
    Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
    J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
    Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer.
    Hata Y; Takahashi H; Todo S; Okazaki M; Asaishi K; Hirata K; Okushiba S; Kato H; Uchino J
    Breast Cancer; 2003; 10(2):134-9. PubMed ID: 12736566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
    Fountzilas G; Stathopoulos G; Kouvatseas G; Polychronis A; Klouvas G; Samantas E; Zamboglou N; Kyriakou K; Adamou A; Pectasidis D; Ekonomopoulos T; Kalofonos HP; Bafaloukos D; Georgoulias V; Razis E; Koukouras D; Zombolas V; Kosmidis P; Skarlos D; Pavlidis N;
    Am J Clin Oncol; 2004 Feb; 27(1):57-67. PubMed ID: 14758135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.
    Yang H; Zong X; Yu Y; Shao G; Zhang L; Qian C; Bian Y; Xu X; Sun W; Meng X; Ding X; Chen D; Zou D; Xie S; Zheng Y; Zhang J; He X; Sun C; Yu X; Ni J
    Br J Cancer; 2013 Aug; 109(3):582-8. PubMed ID: 23860520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.